Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Apacef
2. Apatef
3. Cefotan
4. Cefotetan Disodium
5. Cefotetan Disodium Salt
6. Ceftotan
7. Disodium Salt, Cefotetan
8. Disodium, Cefotetan
9. Ici 156834
10. Ici-156834
11. Ici156834
12. Salt, Cefotetan Disodium
13. Ym 09330
14. Ym-09330
15. Ym09330
1. 69712-56-7
2. Cefotetanum
3. Apacef
4. Cefotetanum [inn-latin]
5. Ici 156834
6. Ici-156834
7. Ici 156,834
8. 48spp0pa9q
9. Mls002153829
10. Chebi:3499
11. Ici-156,834
12. Ym 09330
13. Nsc-760045
14. (6r,7s)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
15. Smr001233197
16. (6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5- Yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- Carboxylic Acid
17. 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic Acid
18. Cefotetan Acid
19. (6r,7s)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
20. Unii-48spp0pa9q
21. Cefotetan [usan:usp:inn:ban]
22. Ncgc00016914-01
23. Einecs 274-093-3
24. Cas-69712-56-7
25. Ici156834
26. Brn 1208088
27. Cefotetan [inn]
28. Cefotetan [jan]
29. Cefotetan [mi]
30. Cefotetan [usan]
31. Prestwick0_000473
32. Prestwick1_000473
33. Prestwick2_000473
34. Prestwick3_000473
35. Cefotetan [vandf]
36. Dsstox_cid_2762
37. Cefotetan [mart.]
38. Cefotetan [who-dd]
39. Dsstox_rid_76720
40. Dsstox_gsid_22762
41. Schembl61376
42. Bspbio_000606
43. (6r,7s)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid
44. Cid_53025
45. Spbio_002545
46. Cefotetan (jp17/usp/inn)
47. Bpbio1_000668
48. Chembl474579
49. Cefotetan [usp Impurity]
50. Dtxsid1022762
51. Bdbm80643
52. Gtpl10936
53. Cefotetan [usp Monograph]
54. Hms1569o08
55. Hms2096o08
56. Hms2234c15
57. Hms3713o08
58. Amy28799
59. Bcp10745
60. Hy-n6670
61. Zinc3830441
62. Tox21_110681
63. Mfcd00864983
64. Akos015896100
65. Ac-2141
66. Ccg-220473
67. Db01330
68. Nsc 760045
69. Ncgc00016914-06
70. Ncgc00179507-01
71. (6r,7s)-4-((2-carboxy-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)carbamoyl)-1,3-dithietane-delta(sup 2,alpha)-malonamic Acid
72. (6r,7s)-7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
73. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7alpha))-
74. As-56133
75. Ab00513847
76. Cs-0092723
77. C06886
78. D00260
79. Cefotetan, Antibiotic For Culture Media Use Only
80. 712c567
81. A836615
82. Sr-01000842155
83. Q2602246
84. Sr-01000842155-3
85. W-104601
86. (6r,7s)-4-((2-carboxy-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)carbamoyl)-1,3-dithietane-.delta.(sup 2,.alpha.)-malonamic Acid
87. (6r,7s)-7-(4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carboxamido)-7-methoxy-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
88. (6r,7s)-7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]-oxomethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
89. (6r,7s)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
90. (6r,7s)-7-[[4-(2-amino-1-carboxy-2-keto-ethylidene)-1,3-dithietane-2-carbonyl]amino]-8-keto-7-methoxy-3-[[(1-methyltetrazol-5-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
91. (6r,7s)-7-[[4-[1-azanyl-3-oxidanyl-1,3-bis(oxidanylidene)propan-2-ylidene]-1,3-dithietan-2-yl]carbonylamino]-7-methoxy-3-[(1-methyl-1,2,3,4-tetrazol-5-yl)sulfanylmethyl]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
92. Disodium 7-[[4-(2-amino-1-carboxylato-2-oxo-ethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Molecular Weight | 575.6 g/mol |
---|---|
Molecular Formula | C17H17N7O8S4 |
XLogP3 | 0.1 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 9 |
Exact Mass | 575.00214522 g/mol |
Monoisotopic Mass | 575.00214522 g/mol |
Topological Polar Surface Area | 321 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 1090 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Cefotetan |
PubMed Health | Cefotetan (Injection) |
Drug Classes | Antibiotic |
Drug Label | CEFOTAN (cefotetan disodium for injection) and CEFOTAN (cefotetan injection) in Galaxy * plastic container (PL 2040) as cefotetan disodium are sterile, semisynthetic, broad-spectrum, beta-lactamase resistant, cephalosporin (cephamycin) antibiotics... |
Active Ingredient | Cefotetan disodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 10gm base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Fresenius Kabi Usa; West-ward Pharm |
2 of 2 | |
---|---|
Drug Name | Cefotetan |
PubMed Health | Cefotetan (Injection) |
Drug Classes | Antibiotic |
Drug Label | CEFOTAN (cefotetan disodium for injection) and CEFOTAN (cefotetan injection) in Galaxy * plastic container (PL 2040) as cefotetan disodium are sterile, semisynthetic, broad-spectrum, beta-lactamase resistant, cephalosporin (cephamycin) antibiotics... |
Active Ingredient | Cefotetan disodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 10gm base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Fresenius Kabi Usa; West-ward Pharm |
For prophylaxis and treatment of bacterial infections.
FDA Label
Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DC - Second-generation cephalosporins
J01DC05 - Cefotetan
Route of Elimination
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.
Volume of Distribution
10.4 L [elderly patients (greater than 65 years) with normal renal function]
10.3 L [healthy volunteers (aged 25 to 28 years)]
Clearance
1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)]
1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.
In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged
The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis.
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cefotetan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefotetan, including repackagers and relabelers. The FDA regulates Cefotetan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefotetan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefotetan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cefotetan supplier is an individual or a company that provides Cefotetan active pharmaceutical ingredient (API) or Cefotetan finished formulations upon request. The Cefotetan suppliers may include Cefotetan API manufacturers, exporters, distributors and traders.
click here to find a list of Cefotetan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cefotetan DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefotetan active pharmaceutical ingredient (API) in detail. Different forms of Cefotetan DMFs exist exist since differing nations have different regulations, such as Cefotetan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefotetan DMF submitted to regulatory agencies in the US is known as a USDMF. Cefotetan USDMF includes data on Cefotetan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefotetan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefotetan suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefotetan Drug Master File in Korea (Cefotetan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefotetan. The MFDS reviews the Cefotetan KDMF as part of the drug registration process and uses the information provided in the Cefotetan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefotetan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefotetan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefotetan suppliers with KDMF on PharmaCompass.
Cefotetan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefotetan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefotetan GMP manufacturer or Cefotetan GMP API supplier for your needs.
A Cefotetan CoA (Certificate of Analysis) is a formal document that attests to Cefotetan's compliance with Cefotetan specifications and serves as a tool for batch-level quality control.
Cefotetan CoA mostly includes findings from lab analyses of a specific batch. For each Cefotetan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefotetan may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefotetan EP), Cefotetan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefotetan USP).
LOOKING FOR A SUPPLIER?